Description: Dong-A Socio Holdings Co., Ltd. engages in the pharmaceutical business in South Korea and internationally. It offers Bacchus, Benachio, and Tempo; infection management products; imaging equipment, such as FX-V1 and CLS-S7 for surgery and diagnosis; and MEDIFLIX, a medical knowledge-sharing platform. The company provides business management services; CMO services, including pre-clinical study, clinical trial, and commercial production of antibodies and recombinant proteins; maintenance, repair, and operation; quarantine; and military logistics services; and packaging and parcel delivery services. In addition, it offers mineral water under the Gayasan Cheonnyeonsu brand; POCARI SWEAT; Narangd cider; Oronamin C; Oran-C bio-PET; and STP2104, an mRNA based COVID-19 vaccine, which is in phase I clinical trial. Further, the company engages in the construction of industrial facilities, such as bio, pharmaceutical, food, logistics warehouses, education/research facilities, work/sales facilities, and public facilities; provides design, maintenance, and asset development services. Additionally, it provides IT systems development and maintenance. The company was founded in 1932 and is headquartered in Seoul, South Korea.
Home Page: www.donga.co.kr
64, Cheonho-daero
Seoul,
02587
South Korea
Phone:
82 2 920 8421
Officers
| Name | Title |
|---|---|
| Mr. Jae-Hun Jung | CEO, VP & Inside Director |
| Seung Hyun Ko | Exec. Director & CFO |
| Ms. Soo-Jung Park | Sr. Managing Director of Management Strategy |
| Mr. Eun-seok Lee | Managing Director of Management Planning |
| Sang Hwan Baek | Exec. Director of Management & Planning and Inside Director |
| Mr. Soo-Hyoung Kang | Chief Exec. Officer of Dong-A ST & Pres of Dong-A ST |
| Lee Seong Hui | Assistant Managing Director |
Exchange: KO
Country: KR : Korea (Republic of)
Currency: Korean Won (₩)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.6333 |
| Price-to-Sales TTM: | 0.6422 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 90 |